Pre-clinical immunogenicity of human papillomavirus alpha-7 and alpha-9 major capsid proteins

Vaccine

Volumn 32, Issue 48, 2014, Pages 6548-6555

  Bissett, Sara L ^a   Mattiuzzo, Giada ^b   Draper, Eve ^a   Godi, Anna ^a   Wilkinson, Dianna E ^b   Minor, Philip ^b   Page, Mark ^b   Beddows, Simon ^a  

^a PUBLIC HEALTH ENGLAND   (United Kingdom)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Antibody; Antigenicity; Diversity; Human papillomavirus; L1; Major capsid protein

Indexed keywords

CAPSID PROTEIN L1; NEUTRALIZING ANTIBODY; VIRUS ANTIBODY; CAPSID PROTEIN; ONCOPROTEIN; WART VIRUS VACCINE;

ALPHAPAPILLOMAVIRUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ARTICLE; CONTROLLED STUDY; CROSS PROTECTION; CROSS REACTION; FEMALE; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 39; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN PAPILLOMAVIRUS TYPE 68; IMMUNOGENICITY; MOUSE; NEW ZEALAND WHITE (RABBIT); NONHUMAN; VIRUS IMMUNITY; VIRUS LIKE AGENT; VIRUS NEUTRALIZATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; GENETICS; GENOTYPE; HEK293 CELL LINE; HUMAN; IMMUNOLOGY; RABBIT; SERODIAGNOSIS;

ALPHAPAPILLOMAVIRUS; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CAPSID PROTEINS; CROSS PROTECTION; FEMALE; GENOTYPE; HEK293 CELLS; HUMANS; MICE, INBRED BALB C; NEUTRALIZATION TESTS; ONCOGENE PROTEINS, VIRAL; PAPILLOMAVIRUS VACCINES; RABBITS;

EID: 84908584184     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.07.116     Document Type: Article

References (48)

1. Schiller J.T., Castellsague X., Garland S.M. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012, 30(Suppl. 5):F123-F138.
2. de Sanjose S., Quint W.G., Alemany L., Geraets D.T., Klaustermeier J.E., Lloveras B., et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11:1048-1056.
3. Li N., Franceschi S., Howell-Jones R., Snijders P.J., Clifford G.M. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2010, 128:927-935.
4. Tabrizi S.N., Brotherton J.M., Kaldor J.M., Skinner S.R., Cummins E., Liu B., et al. Fall in human papillomavirus prevalence following a national vaccination program. J Infect Dis 2012, 206:1645-1651.
5. Markowitz L.E., Hariri S., Lin C., Dunne E.F., Steinau M., McQuillan G., et al. Reduction in human papillomavirus (HPV) prevalence among young women following HPV vaccine introduction in the United States, National Health and Nutrition Examination Surveys, 2003-2010. J Infect Dis 2013, 208:385-393.
6. Mesher D., Soldan K., Howell-Jones R., Panwar K., Manyenga P., Jit M., et al. Reduction in HPV 16/18 prevalence in sexually active young women following the introduction of HPV immunisation in England. Vaccine 2013, 32:26-32.
7. Sonnenberg P., Clifton S., Beddows S., Field N., Soldan K., Tanton C., et al. Prevalence, risk factors, and uptake of interventions for sexually transmitted infections in Britain: findings from the National Surveys of Sexual Attitudes and Lifestyles (Natsal). Lancet 2013, 382:1795-1806.
8. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Edwards R.P., Zepp F., et al. Comparison of the immunogenicity and safety of Cervarix and Gardasil human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccines 2009, 5:705-719.
9. Kemp T.J., Garcia-Pineres A., Falk R.T., Poncelet S., Dessy F., Giannini S.L., et al. Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women. Vaccine 2008, 26:3608-3616.
10. Draper E., Bissett S.L., Howell-Jones R., Waight P., Soldan K., Jit M., et al. A randomized, observer-blinded immunogenicity trial of Cervarix((R)) and Gardasil((R)) Human Papillomavirus vaccines in 12-15 year old girls. PLOS ONE 2013, 8:e61825.
11. Suzich J.A., Ghim S.J., Palmer-Hill F.J., White W.I., Tamura J.K., Bell J.A., et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci U S A 1995, 92:11553-11557.
12. Breitburd F., Kirnbauer R., Hubbert N.L., Nonnenmacher B., Trin-Dinh-Desmarquet C., Orth G., et al. Immunization with virus like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995, 69:3959-3963.
13. Longet S., Schiller J.T., Bobst M., Jichlinski P., Nardelli-Haefliger D. A murine genital-challenge model is a sensitive measure of protective antibodies against human papillomavirus infection. J Virol 2011, 85:13253-13259.
14. Stanley M. Potential mechanisms for HPV vaccine-induced long-term protection. Gynecol Oncol 2010, 118:S2-S7.
15. Wheeler C.M., Castellsague X., Garland S.M., Szarewski A., Paavonen J., Naud P., et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:100-110.
16. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199:926-935.
17. Smith J.F., Brownlow M., Brown M., Kowalski R., Esser M.T., Ruiz W., et al. Antibodies from women immunized with gardasil ((R)) cross-neutralize HPV 45 pseudovirions. Hum Vaccines 2007, 3:109-116.
18. Kemp T.J., Hildesheim A., Safaeian M., Dauner J.G., Pan Y., Porras C., et al. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 2011, 29:2011-2014.
19. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Fox B., Scholar S., et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccines 2011, 7:1359-1373.
20. Draper E., Bissett S.L., Howell-Jones R., Edwards D., Munslow G., Soldan K., et al. Neutralization of non-vaccine human papillomavirus pseudoviruses from the A7 and A9 species groups by bivalent HPV vaccine sera. Vaccine 2011, 29:8585-8590.
21. Plotkin S.A. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis 2008, 47:401-409.
22. Stanley M. Prospects for new human papillomavirus vaccines. Curr Opin Infect Dis 2010, 23:70-75.
23. Wang J.W., Roden R.B. L2, the minor capsid protein of papillomavirus. Virology 2013, 445:175-186.
24. Joura E. Efficacy and immunogenicity of a novel 9-valent HPV L1 virus-like particle vaccine in 16 to 26 year old women 2013, Eurogin, Florence, Italy, SS 8-4.
25. Safaeian M., Porras C., Pan Y., Kreimer A., Schiller J.T., Gonzalez P., et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) 2013, 6:1242-1250.
26. Dobson S.R., McNeil S., Dionne M., Dawar M., Ogilvie G., Krajden M., et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013, 309:1793-1802.
27. Kreimer A.R., Rodriguez A.C., Hildesheim A., Herrero R., Porras C., Schiffman M., et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011, 103:1444-1451.
28. Combita A.L., Touze A., Bousarghin L., Christensen N.D., Coursaget P. Identification of two cross-neutralizing linear epitopes within the L1 major capsid protein of human papillomaviruses. J Virol 2002, 76:6480-6486.
29. Giroglou T., Sapp M., Lane C., Fligge C., Christensen N.D., Streeck R.E., et al. Immunological analyses of human papillomavirus capsids. Vaccine 2001, 19:1783-1793.
30. Ochi H., Kondo K., Matsumoto K., Oki A., Yasugi T., Furuta R., et al. Neutralizing antibodies against human papillomavirus types 16, 18, 31, 52, and 58 in serum samples from women in Japan with low-grade cervical intraepithelial neoplasia. Clin Vaccine Immunol 2008, 15:1536-1540.
31. Buck C.B., Day P.M., Trus B.L. The papillomavirus major capsid protein L1. Virology 2013, 445:169-174.
32. Culp T.D., Spatz C.M., Reed C.A., Christensen N.D. Binding and neutralization efficiencies of monoclonal antibodies, Fab fragments, and scFv specific for L1 epitopes on the capsid of infectious HPV particles. Virology 2007, 361:435-446.
33. ® human papillomavirus vaccine display a range of Alpha-9 inter-type specificities. Vaccine 2014, 32:1139-1146.
34. Huo Z., Bissett S.L., Giemza R., Beddows S., Oeser C., Lewis D.J. Systemic and mucosal immune responses to sublingual or intramuscular human papilloma virus antigens in healthy female volunteers. PLOS ONE 2012, 7:e33736.
35. Giannini S.L., Hanon E., Moris P., Van Mechelen M., Morel S., Dessy F., et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only. Vaccine 2006, 24:5937-5949.
36. Pastrana D.V., Buck C.B., Pang Y.Y., Thompson C.D., Castle P.E., FitzGerald P.C., et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004, 321:205-216.
37. Tamura K., Dudley J., Nei M., Kumar S. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol Biol Evol 2007, 24:1596-1599.
38. Bishop B., Dasgupta J., Klein M., Garcea R.L., Christensen N.D., Zhao R., et al. Crystal structures of four types of human papillomavirus L1 capsid proteins: understanding the specificity of neutralizing monoclonal antibodies. J Biol Chem 2007, 282:31803-31811.
39. Chen X.S., Garcea R.L., Goldberg I., Casini G., Harrison S.C. Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 2000, 5:557-567.
40. Brown M.J., Seitz H., Towne V., Muller M., Finnefrock A.C. Development of neutralizing monoclonal antibodies for oncogenic HPV types 31, 33, 45, 52, and 58. Clin Vaccine Immunol 2014, 21:587-593.
41. Carter J.J., Wipf G.C., Benki S.F., Christensen N.D., Galloway D.A. Identification of a human papillomavirus type 16-specific epitope on the C-terminal arm of the major capsid protein L1. J Virol 2003, 77:11625-11632.
42. Zhang T., Xu Y., Qiao L., Wang Y., Wu X., Fan D., et al. Trivalent Human Papillomavirus (HPV) VLP vaccine covering HPV type 58 can elicit high level of humoral immunity but also induce immune interference among component types. Vaccine 2010, 28:3479-3487.
43. Brendle S.A., Culp T.D., Broutian T.R., Christensen N.D. Binding and neutralization characteristics of a panel of monoclonal antibodies to human papillomavirus 58. J Gen Virol 2010, 91:1834-1839.
44. Rizk R.Z., Christensen N.D., Michael K.M., Muller M., Sehr P., Waterboer T., et al. Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J Gen Virol 2008, 89:117-129.
45. Scherpenisse M., Schepp R.M., Mollers M., Meijer C.J., Berbers G.A., van der Klis F.R. Characteristics of HPV-specific antibody responses induced by infection and vaccination: cross-reactivity, neutralizing activity, avidity and IgG subclasses. PLOS ONE 2013, 8:e74797.
46. Van de Velde N., Boily M.C., Drolet M., Franco E.L., Mayrand M.H., Kliewer E.V., et al. Population-level impact of the bivalent, quadrivalent, and nonavalent human papillomavirus vaccines: a model-based analysis. J Natl Cancer Inst 2012, 104:1712-1723.
47. Van Damme P., Leroux-Roels G., Simon P., Foidart J.M., Donders G., Hoppenbrouwers K., et al. Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: results from two randomized trials. Vaccine 2014, 32:3694-3705.
48. Kemp T.J., Safaeian M., Hildesheim A., Pan Y., Penrose K.J., Porras C., et al. Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix((R)). Vaccine 2012, 31:165-170.